Wells Drew A, Cleveland Kerry O, Jacobs Anna, Patterson Shanise, Mason Darius
University Hospital, Methodist Le Bonheur Healthcare - University Hospital, Memphis, TN, USA.
Infectious Diseases, Methodist Le Bonheur Healthcare - University Hospital, Memphis, TN, USA.
Hosp Pharm. 2023 Aug;58(4):396-400. doi: 10.1177/00185787231151864. Epub 2023 Jan 26.
Ceftriaxone is a commonly utilized antibiotic for the treatment of urinary tract infections (UTI) despite the limited literature supporting its use. Opportunities for antimicrobial stewardship (ASP), including IV-to-PO conversions and de-escalation of therapy, are often missed in the hospital setting.
The study reported here describes the utilization of ceftriaxone in patients admitted to the hospital and treated for UTIs in a large health system, focusing on opportunities for IV-to-PO conversion of antibiotic therapy.
This was a multi-center, retrospective, descriptive study conducted in a large health system. Patients admitted from January 2019 to July 2019 were included for analysis if they were 18 years or older at admission, diagnosed with acute cystitis, acute pyelonephritis, or unspecified UTI, and received two or more doses of ceftriaxone. The primary outcome was to evaluate the percentage of patients who were eligible for conversion from IV ceftriaxone to oral antibiotics while admitted to the hospital based on the defined criteria for automatic pharmacist conversion in the health system. Percentage of urine cultures with susceptibility to cefazolin, the duration of antibiotic therapy in the hospital, and an evaluation of oral antibiotics prescribed at discharge were also recorded.
A total of 300 patients were included; 88% met the pre-specified criteria for IV-to-PO conversion, but only 12% were converted from IV-to-PO antibiotics during hospitalization. Approximately 65% of patients remained on IV ceftriaxone until discharge, at which time they were converted to a PO antibiotic, most commonly fluoroquinolones followed by third-generation cephalosporins.
Patients admitted to the hospital and receiving treatment with ceftriaxone for UTI were infrequently converted to oral therapy prior to discharge despite meeting criteria for automatic pharmacist IV-to-PO conversion. Findings highlight opportunities to contribute to antimicrobial stewardship initiatives across the health system and the importance of tracking and reporting results to frontline providers.
尽管支持使用头孢曲松治疗尿路感染(UTI)的文献有限,但它仍是常用的抗生素。在医院环境中,抗菌药物管理(ASP)的机会,包括静脉给药到口服给药的转换和治疗降级,常常被错过。
本文报道的研究描述了在一个大型医疗系统中,住院并接受UTI治疗的患者使用头孢曲松的情况,重点关注抗生素治疗从静脉给药转换为口服给药的机会。
这是一项在大型医疗系统中进行的多中心、回顾性、描述性研究。2019年1月至2019年7月入院的患者,如果入院时年龄在18岁及以上,被诊断为急性膀胱炎、急性肾盂肾炎或未明确的UTI,并接受了两剂或更多剂量的头孢曲松,则纳入分析。主要结果是根据医疗系统中自动药师转换的既定标准,评估住院期间符合从静脉注射头孢曲松转换为口服抗生素条件的患者百分比。还记录了对头孢唑林敏感的尿培养百分比、住院期间的抗生素治疗持续时间以及出院时开具的口服抗生素评估情况。
共纳入300例患者;88%符合静脉给药到口服给药转换的预先设定标准,但住院期间只有12%从静脉注射抗生素转换为口服抗生素。约65%的患者直到出院时仍使用静脉注射头孢曲松,出院时转换为口服抗生素,最常用的是氟喹诺酮类,其次是第三代头孢菌素。
尽管符合自动药师静脉给药到口服给药转换标准,但住院并接受头孢曲松治疗UTI的患者在出院前很少转换为口服治疗。研究结果突出了在整个医疗系统中促进抗菌药物管理举措的机会,以及向一线提供者跟踪和报告结果的重要性。